Audentes Therapeutics — Investor Presentation (September 2016)
34 slides from Audentes Therapeutics's investor presentation, Sep 28, 2016
Slide 1: Audentes Corporate Overview
September 2016 Audentes Corporate Overview NASDAQ: BOLD Exhibit 99.1
Slide 2: Safe Harbor
Safe Harbor Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause event
Slide 3: Audentes Therapeutics
Audentes Therapeutics Developing gene therapy products to transform the lives of rare disease patients with limited or no treatment options Rare disease and AAV gene therapy strategic focus Internal manufacturing provides core strategic advantage Focused selection criteria for current and future pro
Slide 4: Leadership Team with Outstanding Experience
Matthew Patterson President and Chief Executive Officer Natalie Holles Senior VP and Chief Operating Officer Thomas Soloway Senior VP and Chief Financial Officer Suyash Prasad, M.D. Senior VP and Chief Medical Officer John Gray, Ph.D. Senior VP, Research and Development Mary Newman Senior VP, Regula
Slide 5: Multiple 2016 Sector Catalysts
Multiple 2016 Sector Catalysts Hemophilia A&B - Spinal Muscular Atrophy Choroideremia - X-linked Retinoschisis Parkinson’s - Sanfilippo B AAV9-SMN for SMA Type 1 A devastating rare disease affecting infants Compelling proof-of-concept for treating neuromuscular disease with systemic AAV gene therapy
Slide 6: Focused Approach to Product Candidate Selection
Focused Approach to Product Candidate Selection Value Drivers Audentes Approach High-value targets Serious life-threatening rare diseases with limited or no treatment options Monogenic diseases with well-understood biology High potential for meaningful clinical benefits Leading AAV science Well-char
Slide 7: Robust Pipeline
[Enter Text Here]---[Enter Text Here] Robust Pipeline Product Candidate(Indication)Stage of DevelopmentPlanned IND/CTA SubmissionPreliminary Data ExpectedCommercial RightsDiscoveryLead OptimizationIND- EnablingPhase 1/2AT132(XLMTM)Q1 2017Q4 2017AT342(Crigler-Najjar Syndrome)Q4 2016Q4 2017AT982(Pompe
Slide 8: Internal cGMP manufacturing capability
Internal manufacturing capability is a significant advantage in AAV field Superior control over timelines, costs, and intellectual property Opportunity for rapid addition of new programs Audentes facility established and on-line 38,000 square foot cGMP manufacturing facility in South San Francisco 2
Slide 9: Audentes Manufacturing Positioned for Leadership in AAV Production
Audentes Manufacturing Positioned for Leadership in AAV Production Mammalian cell-based production Natural host for AAV Significant regulatory history with HEK293 Robust, industrial scale suspension culture system Proprietary downstream purification optimizes product quality and purity Initial capac
Slide 10: AT132 X-linked myotubular myopathy
AT132 X-linked myotubular myopathy
Slide 11: XLMTM: A Fatal Disease with No Treatment Options
Serious, life-threatening rare disease Significant impairment of respiratory and neuromuscular function Estimated 50% mortality by 18 months Incidence: 1 in 50K newborn males Monogenic, well-understood biology MTM1 gene encodes myotubularin, enzyme required for normal development and function of ske
Slide 12: AT132 Improves Survival in XLMTM Mouse and Dog Models
A single treatment with AT132 Results In Dramatic Improvement & Survival in XLMTM Mouse and Dog Models M. K. Childers et al., Sci Transl Med, 2014; Buj-Bello, et al. Human Molecular Genetics, 2008; Note: vector dosing numbers have been adjusted from publication as a result of improvements in titrati
Slide 13: AT132 Improves Survival in XLMTM Dogs
Treatment with AT132 Results in Dramatic Improvement and Survival in XLMTM Dogs *Dogs 3, 4 and 5, the three dogs treated in the proof-of-concept canine study, achieved a statistically significant improvement in survival.
Slide 14: AT132 Dose Dependent Improvement in XLMTM Dogs
AT132 Improves Survival, Neuromuscular and Respiratory Outcomes in a Dose Dependent Manner in XLMTM Dogs Systemic Delivery Dose-Escalation Study in XLMTM Canine Model Mack, D., et. al. ASGCT, 2015 n=19 Infusion of AT132 in week 10 AT132 treated dogs assessed over 45 weeks Arm n Normal 6 XLMTM + Plac
Slide 15: AT132 Clinical Development
AT132 Clinical Development Planned Path to Phase 1/2 Data RECENSUS Retrospective Chart Review (n=120) XLMTM natural history Historical control for ASPIRO INCEPTUS Clinical Assessment and Phase 1/2 Run-in Study (n=12 to 15) Ongoing, prospective evaluation of disease presentation Longitudinal baseline
Slide 16: AT132 for XLMTM Opportunity Summary
AT132 for XLMTM Opportunity Summary Robust Preclinical POC Path to Approval Compelling Market Potential Consistent significant impact on muscle function and survival across two models of disease Clear dose-dependent efficacy Strong safety profile IND/CTA planned Q1:17 Preliminary clinical data expec
Slide 17: AT342 Crigler-Najjar syndrome
AT342 Crigler-Najjar syndrome
Slide 18: Crigler-Najjar Syndrome
Crigler-Najjar Syndrome A Rare Disease that Leads to Neurological Damage and Death Serious, life-threatening rare disease Significant bilirubin accumulation that can lead to irreversible neurological damage and death Current treatments: > 12 hours/day of phototherapy, liver transplant Estimated inci
Slide 19: AAV8-UGT1A1 Reduces Bilirubin Levels in Mouse Model
AAV8-UGT1A1 Reduces Bilirubin Levels in a Crigler-Najjar Mouse Model Single intraperitoneal injection of AAV8-UGT1A1 (3.2 x 1011 vg/mouse) in 4 day old affected mice Bilirubin levels remained below the level at which neurological damage is observed for the 17-month study duration Results suggest tha
Slide 20: AT342 Development Plan
AT342 Development Plan Planned Path to Phase 1/2 Data Clinical Assessment and Phase 1/2 Run-in Study (n=12 to 15) Prospective evaluation of disease presentation Longitudinal baseline and within-patient control for Phase 1/2 Clinical Study Facilitate enrollment and other operational aspects of Phase
Slide 21: AT342 for Crigler-Najjar Opportunity Summary
AT342 for Crigler-Najjar Opportunity Summary Robust Preclinical POC Path to Approval Compelling Market Potential Rapid, significant, and durable reductions in bilirubin and need for phototherapy in mouse model Established safety track record for liver-directed AAV8 therapies IND/CTA planned Q4:16 Pr
Slide 22: AT982 Pompe Disease
AUDENTES 2» AT982 POMPE DISEASE
Slide 23: Pompe Disease
Pompe Disease A Rare, Severe, Progressive Neuromuscular Disease Lipinksi, Shawn. Molecular Genetics and Metabolism, 2012; Lacana, et al., Amer. J. Medical Genetics, 2012; International Pompe Association, Pompe Community and United Pompe Foundation Serious, life-threatening rare disease Severe muscle
Slide 24: AT982 Significant Improvement in Pompe KO Mice
P ≤ 0.0001 P ≤ 0.05 P ≤ 0.001 P ≤ 0.01 P ≤ 0.05 P ≤ 0.001 P ≤ 0.001 P ≤ 0.001 P ≤ 0.001 P ≤ 0.01 P ≤ 0.01 Treatment with AT982 Results In Significant Improvement in Pompe KO Mice Falk et al, Molecular Therapy–Methods & Clinical Development,2015 GAA Activity Total Respiratory Cycle Time Improved (3 m
Slide 25: AT982 Development Plan
AT982 Development Plan Phase 1/2 proof-of-concept (POC) IND planned Q4:16 Phase 1/2 POC study (n=~8 Pompe adults on ERT) Randomized, blinded, within patient control Intramuscular injection to tibialis anterior (TA) Objectives: Safety and GAA expression after single AT982 injection Exploring potentia
Slide 26: AT982 for Pompe Opportunity Summary
AT982 for Pompe Opportunity Summary Robust Preclinical POC Path to Approval Compelling Market Potential Significant, durable reductions in GAA, improvements in cardiac, respiratory function Clear improvements over ERT in Pompe mouse model Regulatory guidance obtained, IND planned Q4 2016 Preliminary
Slide 27: AT307 CPVT
AT307 Catecholaminergic polymorphic ventricular tachycardia (CPVT)
Slide 28: CASQ2-CPVT: A Life-Threatening Inherited Arrhythmia
Serious, life-threatening rare disease Ventricular arrhythmias and sudden death in response to stress and/or exercise Prevalence estimated at > 6,000 in addressable markets with mortality of 30-50% by age 30 Monogenic , well-understood biology Autosomal recessive form (CASQ2) : gene encodes calseque
Slide 29: AT307 Prototype Prevents VT in Newborn and Adult Mice
AT307 Prototype Prevents VT in Newborn Mice and Reverses VT in Adult Mice A single administration of an AT307 prototype achieved: Near normal levels of CASQ2 protein expression Reduction in pre-arrhythmic events and ventricular tachycardia to normal levels in both newborn and adult mice Denegri et a
Slide 30: AT307 for CASQ2-CPVT Opportunity Summary
AT307 for CASQ2-CPVT Opportunity Summary Robust Proof-of-Concept Path to Approval Compelling Market Potential Significant, durable CASQ2 expression; reduction in ventricular tachycardia in newborn and adult disease model mice IND/CTA planned in 2017 Clear efficacy measures for Phase 1/2 study Orphan
Slide 31: Financial Overview
AUDENTES 2» FINANCIAL OVERVIEW
Slide 32: Financial Summary
Financial Summary $85M IPO in July 2016 with leading life sciences investors (NASDAQ: BOLD) June 30, 2016 cash balance $60.7M of cash and equivalents, short-term investments and short-term restricted cash at June 30 $75.5M IPO proceeds net of underwriting discounts, commissions and offering costs $1
Slide 33: Audentes Highlights
Audentes Highlights Focus Expertise Leadership Manufacturing Catalysts Industry-leading AAV gene therapy company Compelling pipeline of rare disease product candidates Internal cGMP manufacturing expected Q4:16 Future capacity expansion to support full commercial production Proven management team wi
Slide 34: September 2016 Corporate Overview
September 2016 Corporate Overview NASDAQ: BOLD
Audentes Therapeutics — Investor Presentation (September 2016) on 6ix